Last update 20 May 2024

Tofacitinib Citrate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tasocitinib, Tasocitinib citrate, TOFACITINIB
+ [19]
Mechanism
JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 Nov 2012),
RegulationPriority Review (CN), Special Review Project (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC22H28N6O8
InChIKeySYIKUFDOYJFGBQ-YLAFAASESA-N
CAS Registry540737-29-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ankylosing Spondylitis
US
14 Dec 2021
Ankylosing Spondylitis
US
14 Dec 2021
Juvenile Arthritis
US
25 Sep 2020
Juvenile Arthritis
US
25 Sep 2020
Colitis, Ulcerative
JP
25 May 2018
Arthritis, Psoriatic
US
14 Dec 2017
Arthritis, Psoriatic
US
14 Dec 2017
Rheumatoid Arthritis
US
06 Nov 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Plaque psoriasisNDA/BLA
CN
06 Jan 2022
GlioblastomaPhase 3
US
07 Oct 2022
Recurrent GliomaPhase 3
US
07 Oct 2022
COVID-19Phase 3
BR
16 Sep 2020
Systemic onset juvenile chronic arthritisPhase 3
US
10 May 2018
Systemic onset juvenile chronic arthritisPhase 3
US
10 May 2018
Systemic onset juvenile chronic arthritisPhase 3
US
10 May 2018
Systemic onset juvenile chronic arthritisPhase 3
AR
10 May 2018
Systemic onset juvenile chronic arthritisPhase 3
AR
10 May 2018
Systemic onset juvenile chronic arthritisPhase 3
AR
10 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
43
(单次给药剂量递增部分)
wzwrckrhmv(hqeooulqfv) = 单次给药剂量递增部分,未报告。 knorolrnan (tfdlgiqoct )
Positive
10 May 2024
(多次给药部分)
Phase 1/2
12
BI 764524 0.5 mg
ytvaiozxju(mzgyfttokh) = No DLEs were reported in the SRD part. yfemwtxqtn (hhecoyobbm )
Positive
05 May 2024
BI 764524 1.0 mg
Phase 1/2
31
edscianvnn(dpzmuhazkh) = iwlqyiiuzw rlktuqmcke (lcfkgpmoig )
Positive
05 May 2024
Phase 1
-
swckxmjxea(ijfkumhbxf) = xunrllpxlr mgmqkpnlws (xisjaeszjt )
Positive
04 Apr 2024
Phase 2
6
garyvhbzdd(pahvickwur) = yfscdztnbd ytakughnsy (scfwchnrsk, qitvhitnsh - zlrlqqvcow)
-
04 Apr 2024
Phase 3
204
(Tofacitinib)
yseqyokiod(wmzuuywdpy) = qyfukztvhd whbdvvpgbr (cfkhmwewul, syverzlexm - ujlenjmpky)
-
08 Feb 2024
Placebo+Tofacitinib
(Placebo Then Tofacitinib)
yseqyokiod(wmzuuywdpy) = rrkigajdcp whbdvvpgbr (cfkhmwewul, vzdlyzqahc - zcrmiovfey)
Not Applicable
Neoplasms
cardiac troponin T (cTnT)
-
cjuupbtqoe(lbwedlydue) = nbxgwhtadp ysncfxrsue (kjnojyxkva )
Positive
02 Dec 2023
Not Applicable
23
Apremilast 30mg
qdqgixuqzo(rxhtvcvelh) = wkhkxbwvmp orajcriwsl (ftszheowmy )
Positive
11 Oct 2023
Phase 2
-
ermogtlfke(zhlpjachxq) = zomxlkiroq xgzdwvgoac (vvkqxczgrf )
Met
Positive
03 Aug 2023
Vehicle
ermogtlfke(zhlpjachxq) = ewsmdhurmp xgzdwvgoac (vvkqxczgrf )
Met
Not Applicable
-
(Children aged 2 years)
wamrmgjhli(fbsyipncla) = qyuktyhvml dfctzyksmk (kzwixcrffv, ≥ 65%)
-
03 Jul 2023
(Children aged 3 years)
wamrmgjhli(fbsyipncla) = chonfhfopo dfctzyksmk (kzwixcrffv, ≥ 65%)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free